BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29170890)

  • 1. CART trials are going ahead.
    Wei J; Han W
    Sci China Life Sci; 2017 Nov; 60(11):1276-1279. PubMed ID: 29170890
    [No Abstract]   [Full Text] [Related]  

  • 2. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 3. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 4. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
    Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
    Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.
    Mato AR; Thompson MC; Nabhan C; Svoboda J; Schuster SJ
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):852-856. PubMed ID: 28826693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adoptive transfer of T lymphocytes].
    Vié H; Clémenceau B
    Transfus Clin Biol; 2017 Sep; 24(3):256-262. PubMed ID: 28648732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cell therapy in refractory large B-cell lymphoma.
    Stirrups R
    Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
    [No Abstract]   [Full Text] [Related]  

  • 11. Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.
    Guo Y; Wang Y; Han W
    J Immunol Res; 2016; 2016():3850839. PubMed ID: 26998495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safer CARS.
    Heslop HE
    Mol Ther; 2010 Apr; 18(4):661-2. PubMed ID: 20357776
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status of genetic modification of T cells for cancer treatment.
    Dotti G; Heslop HE
    Cytotherapy; 2005; 7(3):262-72. PubMed ID: 16081353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
    Zhang Q; Li H; Yang J; Li L; Zhang B; Li J; Zheng J
    Curr Gene Ther; 2013 Feb; 13(1):65-70. PubMed ID: 23256743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced T-Cell Engineering for Cancer Therapy (ATECT).
    Hum Gene Ther Clin Dev; 2015 Jun; 26(2):78. PubMed ID: 26086751
    [No Abstract]   [Full Text] [Related]  

  • 18. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with T cells bearing chimeric antitumor receptors.
    Paillard F
    Hum Gene Ther; 1999 Jan; 10(2):151-3. PubMed ID: 10022540
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.